bioRxivCell BiologyPreprint
Targeting endothelial FOXO1 protects diabetic β-cells and improves wound healing
H. Wu, K. Cui, B. Zhu, Y. W. Lu, L. SuniD, Q. Ma, A. Jian, D. O. Hurtado, X. Gao, Y. Li, S. Bhattacharjee, H. Fu, A. E. Birsner, M. Malovichko, M. Li, B. Wang, B. Singh, Q. Peng, S. Wong, V. Norton, K. s. Li, S. Eisa-Beygi, D. Wang, D. B. Cowan, D. R. Bielenberg, , H. Chen
Abstract
The forkhead box O1 (FOXO1) transcription factor plays critical roles in regulating not only metabolic activity but also angiogenesis in the vascular endothelium1-4. Our previous studies show that epsin endocytic adaptors can regulate both angiogenesis and lymphangiogenesis5-7. Endothelial cells (ECs) lining the inside of blood vessels are continuously exposed to circulating insulin and insulin-like growth factors (IGFs). Emerging evidences suggest that ECs can affect {beta}-cell function8-11. Excessive IGF2, especially elevated local IGF2 levels in islets, may represent a risk factor for developing diabetes12-15; however, the underlying molecular mechanisms by which aberrant angiogenesis and endothelium-derived factors regulate pancreatic {beta}-cell function in diabetes remain unclear. Here, we report that the pancreas of diabetic patients as well as the pancreas, skin, and plasma of streptozotocin/high fat diet (STZ/HFD)-induced diabetic mice and db/db mice contains excess IGF2, which can lead to {beta}-cell dysfunction and apoptosis. Single-cell transcriptomics combined with mass spectrometry analysis reveal that endothelial-specific knockout of FOXO1 increases circulating soluble and cell-membrane or intracellular expression levels of IGF type 2 receptor (IGF2R) and CCCTC-binding factor (CTCF), while decreasing IGF2 levels in diabetes. Both IGFR215-17 and CTCF18-21 can reduce IGF2 levels and may ameliorate {beta}-cell decline associated with excess IGF2 in diabetes. Furthermore, depletion of FOXO1, epsins, or knockdown of ULK1 inhibits autophagy formation in ECs, preventing degradation of vascular endothelial growth factor receptor 2 (VEGFR2) to promote angiogenesis and improve wound healing in diabetes. Our findings reveal that endothelial FOXO1 regulates epsin-dependent angiogenesis and affects {beta}-cell function and fate through CTCF and IGF2-IGF2R, providing a potential strategy for ameliorating diabetes and accelerating cutaneous wound healing.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Interplay Between FoxM1 and Dab2 Promotes Endothelial Cell Responses in Diabetic Wound Healing
S. Bhattacharjee, J. Gao, … H. Chen·bioRxiv·Feb 7, 2024
- Single-agent Foxo1 inhibition normalizes glycemia and induces gut β-like cells in streptozotocin-diabetic mice
Y.-K. Lee, Y. Nie, … S. Belvedere·bioRxiv·Mar 26, 2022
- Triple Notch/Tgfβ/FoxO1 blockade converts multiple intestinal sub-lineages into β-like cells and lowers glycemia in diabetic animals
- Antagonistic epistasis of Hnf4a and FoxO1 networks through enhancer interactionsin beta-cell function
- A crosstalk between E2F1 and GLP-1 signaling pathways modulates insulin secretion
C. Bourouh, E. Courty, … J.-S. Annicotte·bioRxiv·Apr 16, 2021
- Coordinated interactions between endothelial cells and macrophages in the islet microenvironment promote beta cell regeneration
D. C. Saunders, K. I. Aamodt, … M. Brissova·bioRxiv·Aug 28, 2020